Compugen Ltd. Stock
Your prediction
Pros and Cons of Compugen Ltd. in the next few years
Pros
?
B****
?
C******** o* t** e**********
?
S********** s********
Cons
?
W********* I********* f** t** n*** y****
?
M***** P*******
?
G***** c******* t* c**********
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Compugen Ltd. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Compugen Ltd. | 0.140% | 5.278% | -17.429% | -24.577% | 15.198% | 109.103% | - |
| Protalix Biotherapeutics Inc. | 3.940% | 8.943% | 49.721% | 16.068% | 75.163% | 72.680% | -36.493% |
| Chromadex Corp | -0.970% | -4.651% | -22.642% | -21.154% | -25.455% | 157.619% | -38.346% |
| Intellia Therapeutics Inc | -1.940% | 7.421% | -20.621% | -7.732% | 37.586% | -70.776% | -80.257% |
Comments
Compugen Ltd. (NASDAQ: CGEN) is now covered by analysts at Oppenheimer Holdings Inc.. They set an "outperform" rating and a $4.00 price target on the stock.
Show more
Ratings data for CGEN provided by MarketBeat
Compugen Ltd. (NASDAQ: CGEN) was upgraded by analysts at StockNews.com from a "hold" rating to a "buy" rating.
Show more
Ratings data for CGEN provided by MarketBeat
Compugen Ltd. (NASDAQ: CGEN) had its price target lowered by analysts at Truist Financial Co. from $5.00 to $4.00. They now have a "buy" rating on the stock.
Show more
Ratings data for CGEN provided by MarketBeat
